Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Parkinson’s drug found effective

14.01.2003


A study conducted on 404 patients at several U.S. sites has determined that a new drug called Rasagiline effectively treats early-stage Parkinson’s disease. The study was reported in the December Archives of Neurology.



"These findings are especially important since hopes for treating Parkinson’s with fetal cells were recently dashed," said Technion-Israel Institute of Technology Professor Moussa Youdim, who developed Rasagiline with Prof. John Finberg of the Department of Pharmacology at the Technion.

The study was conducted as part of the clinical trials for FDA approval. Rasagiline is now in the last stage of the approval process with a decision expected later this year. Teva Pharmaceuticals will then market the new drug.


Research participants were randomized in the double-blind, placebo-controlled study. Participants were given 1 or 2 milligrams a day for one week, followed by a 25-week maintenance period.

The treatment’s effectiveness was measured by Unified Parkinson’s Disease Rating Scale (UPDR) and compared with the control group that received a placebo. The group that received 1 milligram showed an improvement of 4.2 UPDR units on average. Those who received 2 milligrams showed an improvement of 3.56 UPDR units.

The report called for further study to evaluate Rasagiline’s long-term effects on the progression of the disease. This is now in progress.

Prof. Youdim heads the Eve Topf Neuro-Degenerative Disease Research and Teaching Center at the Faculty of Medicine at the Technion, where he develops a variety of drugs for neurodegenerative diseases. As early as 1975, Prof. Youdim and colleagues introduced I-Deprenyl (Selegiline), a drug that has been shown to slow the progress of Parkinson’s disease.

Contact: Martha Molnar
e-mail: martha@ats.org

Martha Molnar | EurekAlert!

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>